IL7 and renal cell carcinoma: The main scope of this study was to evaluate the efficacy of an oncolytic adenovirus encoding for human interleukin-7, Ad5/3-E2F-d24-hIL7 (TILT-517), as a treatment for RCC, and its combination with ICIs.